NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.
Sandra M. Swain
Consultant or Advisory Role - Genentech (U); Nektar (U); Novartis (U); Roche (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Sanofi
Other Remuneration - Sanofi
Gong Tang
No relevant relationships to disclose
Charles E. Geyer
No relevant relationships to disclose
Priya Rastogi
No relevant relationships to disclose
James Norman Atkins
No relevant relationships to disclose
Paul P. Donnellan
No relevant relationships to disclose
Louis Fehrenbacher
No relevant relationships to disclose
Catherine A. Azar
No relevant relationships to disclose
Andre Robidoux
No relevant relationships to disclose
Jonathan Polikoff
No relevant relationships to disclose
Adam Brufsky
No relevant relationships to disclose
David D. Biggs
No relevant relationships to disclose
Edward A. Levine
No relevant relationships to disclose
John L. Zapas
No relevant relationships to disclose
Louise Provencher
Honoraria - Amgen
Research Funding - Amgen
Edith A. Perez
No relevant relationships to disclose
Soonmyung Paik
No relevant relationships to disclose
Joseph P. Costantino
No relevant relationships to disclose
Eleftherios P. Mamounas
No relevant relationships to disclose
Norman Wolmark
No relevant relationships to disclose